AstraZeneca Selloff Looks Larger Than the Wainua Valuation Damage

AstraZeneca's stock plummeted 5.7% after its Phase 3 CARDIO-TTRansform trial for heart drug Wainua failed to meet its primary endpoint, erasing $24 billion in market value. However, analysts argue the selloff is an overcorrection, as the failed program represents only ~2% of the company's net present value. The fundamental business remains intact with strong margins, existing drug approvals unchanged, and the $80 billion 2030 revenue target untouched. The market punished the company more for a credibility crack than actual financial damage.

07/10/2026, 2:25 PM • Investing

Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain

Despite expanding biologic adoption and evolving treatment strategies for systemic lupus erythematosus (SLE), research from Spherix Global Insights reveals substantial unmet need remains. While rheumatologists are advancing treatment strategies and increasing biologic utilization, nearly 80% of patients report moderate-to-severe disease with persistent symptoms and frequent flares. Approximately one-third of biologic-treated patients achieve only partial disease control. Recent approvals like Saphnelo® (anifrolumab) and anticipated approvals like Gazyva® (obinutuzumab) for non-renal SLE are expected to expand treatment options.

07/07/2026, 12:58 PM • GlobeNewswire

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The acute kidney injury (AKI) therapeutic pipeline is experiencing robust growth with 20+ pharmaceutical companies developing 25+ pipeline drugs across various clinical stages. Key players including AstraZeneca, Arch Biopartners, Akebia Therapeutics, and others are advancing promising therapies with diverse mechanisms of action. Recent developments include Phase I initiation of AKB-9090, Phase II trial preparations for LSALT peptide, and anticipated Phase III data from AstraZeneca's ARTEMIS trial in H2 2026.

06/23/2026, 1:00 PM • GlobeNewswire

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

AstraZeneca received FDA approval for Truqap (capivasertib) in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, marking the first targeted treatment for this patient population. The Phase III CAPItello-281 trial showed a 19% reduction in disease progression or death risk and a 7.5-month improvement in median radiographic progression-free survival. Additionally, Ultomiris received Priority Review for immunoglobulin A nephropathy treatment, with Phase 3 data showing a 46.6% reduction in proteinuria compared to 5.6% for placebo.

06/15/2026, 12:51 PM • Benzinga

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

AstraZeneca is advancing its oral GLP-1 receptor agonist elecoglipron into Phase 3 trials after demonstrating significant results in Phase 2b studies. The VISTA trial showed 10.5% weight reduction at 26 weeks, while the SOLSTICE trial achieved 1.9% HbA1c reduction in Type 2 diabetes patients. The drug showed a favorable safety profile with mild gastrointestinal side effects.

06/09/2026, 11:46 AM • Benzinga

MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth

MitoRx Therapeutics announces the appointment of Alison Strutt as Chief Financial Officer, László Tankó as Consultant Chief Medical Officer, and Sam Fazeli as Non-Executive Director. These appointments support the company's advancement of MTRX31, a first-in-class small molecule therapy for metabolically unhealthy obesity, towards clinical development following promising preclinical data.

06/09/2026, 7:00 AM • GlobeNewswire

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

AstraZeneca announced that its Phase 3 I CAN trial of Ultomiris (ravulizumab) met its primary endpoint in treating immunoglobulin A nephropathy (IgAN), showing a 46.6% reduction in proteinuria compared to 5.6% for placebo at week 34. The reduction emerged early at week 10 and was sustained through week 34, with consistent safety profile and benefits across patient subgroups.

06/08/2026, 1:02 PM • Benzinga

IEFA: Why This Fund Is One of the Best International ETFs

The iShares Core MSCI EAFE ETF (IEFA) is highlighted as one of the best international ETFs, offering diversified exposure to over 2,600 stocks across 16+ developed markets with a low 0.07% expense ratio and 3.30% dividend yield. While it has underperformed the S&P 500 recently, the fund provides valuable portfolio diversification and could serve as a hedge against U.S. market volatility, particularly if tech stocks decline from current valuations.

06/04/2026, 10:30 AM • The Motley Fool

AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study

AstraZeneca reported updated Phase 3 SERENA-6 trial results showing camizestrant combined with a CDK4/6 inhibitor delivered significant progression-free survival benefits in advanced breast cancer, reducing disease progression or death risk by 55% compared to aromatase inhibitor therapy. Median progression-free survival reached 16.8 months versus 9.2 months for the control group. The drug also showed durable benefits with 99% ctDNA reduction by week eight, though overall survival data remain immature.

06/02/2026, 2:26 PM • Benzinga

AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial

AstraZeneca announced positive Phase 3 EMERALD-3 trial results for its STRIDE immunotherapy regimen combined with lenvatinib and TACE in treating unresectable hepatocellular carcinoma. The combination achieved a 30% reduction in disease progression or death risk and median progression-free survival of 13 months versus 9.8 months with TACE alone, with an encouraging overall survival trend. However, AstraZeneca shares fell 2.69% on the news.

06/01/2026, 1:55 PM • Benzinga

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in Q1 2026, valued at approximately $4.11 million, reducing its stake to 11,000 shares. Despite the fund's reduction, Mineralys stock has surged 87.84% over the past year. The clinical-stage biotech company is awaiting FDA approval for its lead candidate lorundrostat by December 22, 2026, and maintains $646 million in cash.

05/31/2026, 10:19 AM • The Motley Fool